Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | GALR3 | O60755 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | GUSB | P08236 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855474 | 0.89 | HTT (0.75) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL5053541 | 0.87 | HTT (0.73) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL6780760 | 0.84 | HTT (0.72) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL8402836 | 0.83 | HTT (0.75) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL8101445 | 0.83 | HTT (0.68) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL6586520 | 0.83 | IGF1R (0.79) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL4872495 | 0.82 | HTT (0.73) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL19308467 | 0.82 | HTT (0.73) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL13609778 | 0.82 | HTT (0.66) | HTTMEN1KMT2AGALR3RAB9A | |
| SCHEMBL6586139 | 0.82 | HTT (0.66) | HTTMEN1KMT2AGALR3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101039930-B | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt | ACTELION PHARMACEUTICALS LTD | 2010-08-11 | — | — | CN | claimed |
| CN-101039930-A | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-19 | — | — | CN | claimed |
| EP-0630373-A1 | INDOLE DERIVATIVES AS 5HT1C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-28 | — | — | EP | claimed |
| CN-101039930-B | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt | ACTELION PHARMACEUTICALS LTD | 2010-08-11 | — | — | CN | disclosed |
| CN-100424082-C | 4- (piperidinyl-pyrrolidinyl-alkyl-ureido) -quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| CN-101039930-A | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-19 | — | — | CN | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| CN-1681789-A | 1-pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-12 | — | — | CN | disclosed |
| CN-1617869-A | 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-18 | — | — | CN | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | HTT 681/4885MEN1 2285/4885KMT2A 2523/4885 |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | HTT 1465/4885MEN1 871/4885KMT2A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.